BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rostambeigi N, Dekarske AS, Austin EE, Golzarian J, Cressman EN. Cost effectiveness of radioembolization compared with conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Vasc Interv Radiol. 2014;25:1075-1084. [PMID: 24861664 DOI: 10.1016/j.jvir.2014.04.014] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Prince D, Liu K, Xu W, Chen M, Sun JY, Lu XJ, Ji J. Management of patients with intermediate stage hepatocellular carcinoma. Ther Adv Med Oncol 2020;12:1758835920970840. [PMID: 33224278 DOI: 10.1177/1758835920970840] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Yuen SC, Amaefule AQ, Kim HH, Owoo BV, Gorman EF, Mattingly TJ 2nd. A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment. Pharmacoecon Open 2021. [PMID: 34427897 DOI: 10.1007/s41669-021-00298-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Mehta N, Yao FY. Transarterial Radioembolization for Hepatocellular Carcinoma: Who, When… and Y(90)? Gastroenterology 2016;151:1062-5. [PMID: 27983951 DOI: 10.1053/j.gastro.2016.10.031] [Reference Citation Analysis]
4 Akarca US, Akhan O, Bilgiç S, Bozkurt MF, Cantaşdemir M, Çermik TF, Çakaloğlu Y, Er Ö, Ilgıt E, Çapa Kaya G, Küçük NÖ, Numan F, Parıldar M, Türkmen C. The position of transarterial chemoembolization with drug-eluting beads and yttrium-90 transarterial radioembolization in patients with hepatocellular carcinoma: Consensus statements from a Delphi-method expert panel in Turkey. Diagn Interv Radiol 2021;27:732-9. [PMID: 34792027 DOI: 10.5152/dir.2021.201089] [Reference Citation Analysis]
5 Rahman SI, Nunez-Herrero L, Berkes JL. Position 2: Transarterial Radioembolization Should Be the Primary Locoregional Therapy for Unresectable Hepatocellular Carcinoma. Clin Liver Dis (Hoboken) 2020;15:74-6. [PMID: 32226620 DOI: 10.1002/cld.908] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Aly A, Ronnebaum S, Patel D, Doleh Y, Benavente F. Epidemiologic, humanistic and economic burden of hepatocellular carcinoma in the USA: a systematic literature review. Hepat Oncol 2020;7:HEP27. [PMID: 32774837 DOI: 10.2217/hep-2020-0024] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
7 Venkatanarasimha N, Gogna A, Tong KTA, Damodharan K, Chow PKH, Lo RHG, Chandramohan S. Radioembolisation of hepatocellular carcinoma: a primer. Clin Radiol. 2017;72:1002-1013. [PMID: 29032802 DOI: 10.1016/j.crad.2017.07.021] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
8 Rognoni C, Ciani O, Sommariva S, Tarricone R. Cost–effectiveness analysis of treatments involving radioembolization in intermediate-stage hepatocellular carcinoma. Journal of Comparative Effectiveness Research 2018;7:209-21. [DOI: 10.2217/cer-2017-0050] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
9 Roudsari B, McWilliams J, Bresnahan B, Padia SA. Introduction to Cost Analysis in IR: Challenges and Opportunities. J Vasc Interv Radiol 2016;27:539-545.e1. [PMID: 26922978 DOI: 10.1016/j.jvir.2015.12.754] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
10 Kim MA, Jang H, Choi NR, Nam JY, Lee YB, Cho EJ, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ. Yttrium-90 Radioembolization Is Associated with Better Clinical Outcomes in Patients with Hepatocellular Carcinoma Compared with Conventional Chemoembolization: A Propensity Score-Matched Study. J Hepatocell Carcinoma 2021;8:1565-77. [PMID: 34909425 DOI: 10.2147/JHC.S335879] [Reference Citation Analysis]
11 Malagari K, Pomoni A, Filippiadis D, Kelekis D. Chemoembolization of hepatocellular carcinoma with HepaSphere™. Hepat Oncol 2015;2:147-57. [PMID: 30190994 DOI: 10.2217/hep.15.2] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Lentz RW, Messersmith WA. Transarterial Radioembolization in Patients With Unresectable Colorectal Cancer Liver Metastases. J Clin Oncol 2021;39:3887-9. [PMID: 34541862 DOI: 10.1200/JCO.21.01993] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Casadaban LC, Minocha J, Bui JT, Knuttinen MG, Ray CE, Gaba RC. Conventional Ethiodized Oil Transarterial Chemoembolization for Treatment of Hepatocellular Carcinoma: Contemporary Single-Center Review of Clinical Outcomes. American Journal of Roentgenology 2016;206:645-54. [DOI: 10.2214/ajr.15.14758] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Currie BM, Soulen MC. Decision Making: Intra-arterial Therapies for Cholangiocarcinoma-TACE and TARE. Semin Intervent Radiol 2017;34:92-100. [PMID: 28579676 DOI: 10.1055/s-0037-1602591] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
15 Kwon JH, Kim GM, Han K, Won JY, Kim MD, Lee DY, Lee J, Choi W, Kim YS, Kim DY, Han KH. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study. Cardiovasc Intervent Radiol. 2018;41:459-465. [PMID: 29067511 DOI: 10.1007/s00270-017-1826-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Williams SJ, Rilling WS, White SB. Quality of Life and Cost Considerations: Y-90 Radioembolization. Semin Intervent Radiol 2021;38:482-7. [PMID: 34629718 DOI: 10.1055/s-0041-1735570] [Reference Citation Analysis]
17 Walton M, Wade R, Claxton L, Sharif-Hurst S, Harden M, Patel J, Rowe I, Hodgson R, Eastwood A. Selective internal radiation therapies for unresectable early-, intermediate- or advanced-stage hepatocellular carcinoma: systematic review, network meta-analysis and economic evaluation. Health Technol Assess 2020;24:1-264. [PMID: 33001024 DOI: 10.3310/hta24480] [Reference Citation Analysis]
18 Sarwar A, Hawkins CM, Bresnahan BW, Carlos RC, Guimaraes M, Krol KL, Kwan SW, Latif W, Liu R, Marder WD, Ray CE Jr, Banovac F. Evaluating the Costs of IR in Health Care Delivery: Proceedings from a Society of Interventional Radiology Research Consensus Panel. J Vasc Interv Radiol 2017;28:1475-86. [PMID: 29056189 DOI: 10.1016/j.jvir.2017.07.024] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Kallini JR, Gabr A, Salem R, Lewandowski RJ. Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma. Adv Ther. 2016;33:699-714. [PMID: 27039186 DOI: 10.1007/s12325-016-0324-7] [Cited by in Crossref: 67] [Cited by in F6Publishing: 52] [Article Influence: 11.2] [Reference Citation Analysis]
20 Rognoni C, Ciani O, Sommariva S, Bargellini I, Bhoori S, Cioni R, Facciorusso A, Golfieri R, Gramenzi A, Mazzaferro V, Mosconi C, Ponziani F, Sacco R, Trevisani F, Tarricone R. Trans-arterial radioembolization for intermediate-advanced hepatocellular carcinoma: a budget impact analysis. BMC Cancer. 2018;18:715. [PMID: 29976149 DOI: 10.1186/s12885-018-4636-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
21 Patel P, Charles HW, Park J, Deipolyi AR. Arterial Changes Due to Chemoembolization of Hepatocellular Carcinoma Impacting Subsequent Radioembolization. J Vasc Interv Radiol 2016;27:1451-3. [PMID: 27566429 DOI: 10.1016/j.jvir.2016.04.029] [Reference Citation Analysis]
22 Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers (Basel) 2020;12:E791. [PMID: 32224882 DOI: 10.3390/cancers12040791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
23 Likhitsup A, Parikh ND. Economic Implications of Hepatocellular Carcinoma Surveillance and Treatment: A Guide for Clinicians. Pharmacoeconomics 2020;38:5-24. [PMID: 31573053 DOI: 10.1007/s40273-019-00839-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
24 Liu CY, Chen KF, Chen PJ. Treatment of Liver Cancer. Cold Spring Harb Perspect Med 2015;5:a021535. [PMID: 26187874 DOI: 10.1101/cshperspect.a021535] [Cited by in Crossref: 85] [Cited by in F6Publishing: 91] [Article Influence: 12.1] [Reference Citation Analysis]
25 Kwong AJ, Ghaziani TT, Yao F, Sze D, Mannalithara A, Mehta N. National Trends and Waitlist Outcomes of Locoregional Therapy Among Liver Transplant Candidates With Hepatocellular Carcinoma in the United States. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00830-2. [PMID: 34358718 DOI: 10.1016/j.cgh.2021.07.048] [Reference Citation Analysis]
26 Mantry PS, Mehta A, Madani B, Mejia A, Shahin I. Selective internal radiation therapy using yttrium-90 resin microspheres in patients with unresectable hepatocellular carcinoma: a retrospective study. J Gastrointest Oncol 2017;8:799-807. [PMID: 29184683 DOI: 10.21037/jgo.2017.08.03] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
27 Kim DY, Han KH. Transarterial chemoembolization versus transarterial radioembolization in hepatocellular carcinoma: optimization of selecting treatment modality. Hepatol Int 2016;10:883-92. [PMID: 27126821 DOI: 10.1007/s12072-016-9722-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
28 Pan LH, Zhao C, Ma YL. Is Y90 Radioembolization Superior or Comparable to Transarterial Chemoembolization for Treating Hepatocellular Carcinoma? Gastroenterology 2017;152:1627-8. [PMID: 28384449 DOI: 10.1053/j.gastro.2016.10.048] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
29 Zarca K, Mimouni M, Pereira H, Chatellier G, Vilgrain V, Durand-Zaleski I; SARAH Trial Group. Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma. Clin Ther 2021:S0149-2918(21)00213-7. [PMID: 34059326 DOI: 10.1016/j.clinthera.2021.04.018] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Mokdad AA, Singal AG, Yopp AC. Advances in Local and Systemic Therapies for Hepatocellular Cancer. Curr Oncol Rep 2016;18:9. [PMID: 26769114 DOI: 10.1007/s11912-015-0494-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
31 Rognoni C, Ciani O, Sommariva S, Facciorusso A, Tarricone R, Bhoori S, Mazzaferro V. Trans-arterial radioembolization in intermediate-advanced hepatocellular carcinoma: systematic review and meta-analyses. Oncotarget. 2016;7:72343-72355. [PMID: 27579537 DOI: 10.18632/oncotarget.11644] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 7.8] [Reference Citation Analysis]
32 Mahnken AH. Current status of transarterial radioembolization. World J Radiol 2016; 8(5): 449-459 [PMID: 27247711 DOI: 10.4329/wjr.v8.i5.449] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 17] [Article Influence: 4.2] [Reference Citation Analysis]
33 Hectors SJ, Lewis S, Kennedy P, Bane O, Said D, Segall M, Schwartz M, Kim E, Taouli B. Assessment of Hepatocellular Carcinoma Response to 90Y Radioembolization Using Dynamic Contrast Material-enhanced MRI and Intravoxel Incoherent Motion Diffusion-weighted Imaging. Radiol Imaging Cancer 2020;2:e190094. [PMID: 32803165 DOI: 10.1148/rycan.2020190094] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
34 Ahmed O, Patel M, Ward T, Sze DY, Telischak K, Kothary N, Hofmann LV. Cost Accounting as a Tool for Increasing Cost Transparency in Selective Hepatic Transarterial Chemoembolization. Journal of Vascular and Interventional Radiology 2015;26:1820-1826.e1. [DOI: 10.1016/j.jvir.2015.09.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
35 Welling MM, Spa SJ, van Willigen DM, Rietbergen DDD, Roestenberg M, Buckle T, van Leeuwen FWB. In vivo stability of supramolecular host-guest complexes monitored by dual-isotope multiplexing in a pre-targeting model of experimental liver radioembolization. J Control Release 2019;293:126-34. [PMID: 30485797 DOI: 10.1016/j.jconrel.2018.11.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]